Doepo.com

25/09/2026

🙏

18/09/2026

Did you know?

07/09/2026

31/08/2026

A new study is drawing attention to C.B.G as researchers investigate whether the compound could help protect memory under conditions linked to schizophrenia.

In laboratory experiments, researchers found that C.B.G prevented long term memory deficits in an experimental schizophrenia model. The finding is particularly interesting because cognitive problems, including difficulties with learning and memory, can be among the most persistent challenges associated with schizophrenia.

The researchers suggest that C.B.G may influence biological pathways involved in brain signaling and cognitive function. However, the evidence remains preclinical. These experiments were conducted using an experimental model rather than people living with schizophrenia, so the results cannot yet establish whether the same protective effect would occur in humans.

Still, the findings add to growing scientific interest in C.B.G and its potential effects on neurological function. Future research will need to determine the mechanisms involved, whether the findings can be replicated, and whether they translate into meaningful benefits in human studies.

For now, the study offers an intriguing clue rather than a confirmed treatment.

Source: Study on C.B.G and long term memory deficits in an experimental schizophrenia model.

➡️ Note: This content is shared for academic interest, based on scientific studies and historical records. It does not promote, sell, or encourage recreational or non-medical substance use.

30/08/2026

Here's what we know: https://www.sciencealert.com/scientists-discover-a-cannabis-receptor-that-could-stop-breast-cancer-spreading

24/08/2026

Neuropathy is one of those conditions that teaches people pain is not always coming from where they feel it. Burning, tingling, stabbing, numbness, crawling sensations, electric shocks, hypersensitivity, and deep nerve pain can all come from damaged or irritated nerves.

But the real battle often happens in the signaling between pain, inflammation, the immune response, and the nervous system.

That’s where the ECS matters.

In neuropathy, cannabinoids may help the Endocannabinoid system restore balance between pain and inflammation. The ECS helps regulate nociceptive transmission, neuroinflammation, immune signaling, synaptic plasticity, and how loudly the body reports damage.

A 2024 review described the ECS as a critical therapeutic target in neuropathic pain, with CB1 and CB2 receptor pathways connected to pain regulation, neuroinflammation, and cannabinoid treatment potential.

This is why cannabinoids can make the body feel better in ways that go beyond “blocking pain.” THC may help turn down pain perception for some patients. C*D may support inflammatory and stress pathways. CBG, CBC, CBN, CBGa, C*Da, PEA, OEA, and terpenes all belong in the larger conversation because neuropathy is not one signal.

It is a messy storm of nerves, immune cells, inflammation, blood flow, sleep disruption, stress, and recovery.

Clinical research is still mixed and cautious, but it is not empty. A recent updated systematic review found comparable THC-C*D and high THC-to-C*D ratio products may produce small short-term improvements in primarily neuropathic pain, while also increasing common adverse events.
That tells us cannabinoids are not magic, but they are biologically active and deserve careful, personalized use.

For me, the bigger message is this: when the ECS regains balance, the body has a better chance to calm the alarm, lower the inflammatory pressure, and create an environment where healing can happen. Pain relief matters, but repair matters too.

Neuropathy is the nerves screaming, but inflammation often feeds the fire. The ECS is one of the systems that helps turn the volume down so the body can finally start working on the damage.

Mike Robinson, Researcher OG

The endocannabinoid system as a therapeutic target in neuropathic pain: a review
https://pubmed.ncbi.nlm.nih.gov/39317147/
Cannabis-Based Products for Chronic Pain: An Updated Systematic Review
https://pubmed.ncbi.nlm.nih.gov/41429020/
Cannabinoids for Neuropathic Pain: A Pharmacological Review of Mechanisms, Clinical Translation, and Future Directions
https://pubmed.ncbi.nlm.nih.gov/42411099/

23/08/2026

We’ve come to an impasse with cannabinoid medicine in the United States, and the reason is simple: too much of healthcare still doesn’t understand the Endocannabinoid System.

Patients do.

That’s the shift nobody wants to admit. Because of legalization, the advocacy movement, the compassion movement, and the lived experience of patients, many cannabis patients now understand cannabinoid medicine better than the doctors they’re sitting across from.

They understand trial and response, and they understand ratios. They understand THC, C*D, CBG, CBN, acidic cannabinoids, terpenes, route of delivery, timing, tolerance, and the fact that one plant can produce very different outcomes depending on the person using it.

Healthcare wasn't built that way - it's more refined. Most doctors were trained in a model where diagnosis leads to a drug, and insurance companies expect the drug to match the code. That system may work for some things, but it struggles badly with plant medicine because cannabis is not one drug for one problem. It is a library of compounds working with a regulatory system that changes from person to person.

Research has already shown the education gap. A 2022 study found healthcare providers averaged only 58% correct on medical cannabis knowledge questions, and those who pursued self-study or attended cannabis lectures scored higher.

Another 2025 physician-focused paper reported that doctors receive minimal cannabinoid training in medical school, leaving many unprepared to guide patients.

That’s why patients have had to become their own formulators. They mix and match because they live in the body that has to respond. They learn what helps pain without crushing their day, what supports sleep without creating grogginess, what lowers anxiety without flattening emotion, and what helps them reduce opioids, pharmaceuticals, alcohol, or other substances that were making them worse instead of well.

This does not mean doctors don’t matter. It means the system needs humility. Adverse drug events still send hundreds of thousands of Americans to emergency departments every year, and polypharmacy is a real problem in modern care.

We heal best when knowledge of the body meets knowledge of the plant.
And right now, patients are carrying too much of that knowledge alone.

Mike Robinson, Founder
Global Cannabinoid Research Center

Assessing Health Care Providers' Knowledge of Medical Cannabis
https://pmc.ncbi.nlm.nih.gov/articles/PMC9418358/
Physicians' Knowledge, Attitudes, and Perceptions about Medical Cannabis
https://pmc.ncbi.nlm.nih.gov/articles/PMC12162117/
Medication Errors and Adverse Drug Events
https://psnet.ahrq.gov/primer/medication-errors-and-adverse-drug-events